Taiwan, R.O.C.--January 15, 2009 -- InnoPharmax, a specialty biopharmaceutical company based in Taipei, announces the opening of new office and its establishment of dedicated formulation and oncology laboratories in Taiwan.
The total space of the new office and laboratories is 881 m2 and it is located in the center of Neihu Scientific Industry Park. The major renovation of new laboratories include: an isolated manufacturing room for oncology products, a P2-grade laboratory for chemotherapy agents research, and a cell-culture room for drug-related in-vitro studies.
"We are pleased to introduce our new establishment in renovated laboratories. Our company, along with shareholders, has strong commitment and high confidence in our pipeline." said CS Hsu, Ph.D., President for InnoPharmax. "The latest renovation will make a huge lift to our research development in oncology products by accelerating our formulation process in the optimal environment."
InnoPharmax was established in 2005 and The Company’s Research and Development group is working in tandem with select universities and academic institutions on novel delivery vehicles with the aim of improving drug in-vivo performance, and is fully dedicated to conducting clinical research for new drugs in oncology and immunology in bringing clinical benefits to patients suffering from unmet medical needs.
For more information, please contact us through: business@innopharmax.com
